Bridging biological cfDNA features and machine learning approaches

Trends Genet. 2023 Apr;39(4):285-307. doi: 10.1016/j.tig.2023.01.004. Epub 2023 Feb 13.

Abstract

Liquid biopsies (LBs), particularly using circulating tumor DNA (ctDNA), are expected to revolutionize precision oncology and blood-based cancer screening. Recent technological improvements, in combination with the ever-growing understanding of cell-free DNA (cfDNA) biology, are enabling the detection of tumor-specific changes with extremely high resolution and new analysis concepts beyond genetic alterations, including methylomics, fragmentomics, and nucleosomics. The interrogation of a large number of markers and the high complexity of data render traditional correlation methods insufficient. In this regard, machine learning (ML) algorithms are increasingly being used to decipher disease- and tissue-specific signals from cfDNA. Here, we review recent insights into biological ctDNA features and how these are incorporated into sophisticated ML applications.

Keywords: cell-free DNA (cfDNA); circulating tumor DNA (ctDNA); fragmentomics; machine learning (ML); methylomics; nucleosomics.

Publication types

  • Review

MeSH terms

  • Cell-Free Nucleic Acids* / genetics
  • Circulating Tumor DNA* / analysis
  • Circulating Tumor DNA* / genetics
  • Hematologic Neoplasms*
  • Humans
  • Machine Learning
  • Neoplasms* / genetics
  • Precision Medicine

Substances

  • Cell-Free Nucleic Acids
  • Circulating Tumor DNA